Another previous report showed that SIRT1 could inhibit TGF-β1-induced glomerular mesangial cell apoptosis via Smad7 deacetylation [79], and overexpression of SIRT1 attenuated ROS-induced apoptosis in mesangial cells through p53 deacetylation and provided a new therapeutic strategy for kidney glomerular diseases [80]; TSG has been proven to protect DN through inhibiting TGF-β1 expression partially mediated by SIRT1 activation [81]. The gene discussed is TGFB1; the disease is liver dysplastic nodule.